Top in hem/onc: Pay gap in academic medicine, FDA approvals for GI cancers
Click Here to Manage Email Alerts
A first-ever nationwide analysis of full-time academic medicine faculty revealed disparities in pay for men and women and across ethnicities and races, with women earning less than men regardless of race and ethnicity.
Amy S. Gottlieb, MD, FACP, chief faculty development officer at Baystate Health and associate dean for faculty affairs and professor of medicine and OB/GYN at UMass Chan Medical School–Baystate, spoke with Healio about the report’s findings, ways to narrow the gender pay gap and the knowledge that women and institutions can glean from a book she wrote on the topic. It was the top story in hematology/oncology last week.
Another top story highlighted a presentation at the Chemotherapy Foundation Symposium on recent treatment advancements in GI cancers, including the FDA approvals of immunotherapies such as nivolumab (Opdivo, Bristol Myers Squibb) and pembrolizumab (Keytruda, Merck).
Read these and more top stories in hematology/oncology below:
Report highlights wide pay gap for women, minorities in medicine
The Association of American Medical Colleges, or AAMC, recently published the first-ever, national-level analysis of full-time faculty salaries in academic medicine by gender, race and ethnicity. Read more.
FDA approvals in gastrointestinal cancers spark excitement in field
FDA approvals of immunotherapies are among several exciting developments during the past couple of years in the field of upper GI cancers, according to a speaker at Chemotherapy Foundation Symposium. Read more.
Insight into how financial advisors charge for their services
Survey data show that, generally, investors do not understand how much their advisors charge for their services. Read more.
Lack of insurance ’completely’ accounts for lower cancer screening rates among unemployed
Unemployment appeared to be associated with a lower likelihood of having health insurance and of being up to date on cancer screening tests, according to results of a study published in Cancer. Read more.
New-onset diabetes provides ‘window of opportunity’ for early pancreatic cancer detection
Pancreatic cancer often is called the silent killer. Read more.